Try our Advanced Search for more refined results
5,834,025
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
- February 24, 2011 Celgene Strikes $78M Deal In Elan Abraxane IP Suit
- June 16, 2008 Elan Wins $55M From Abraxis In Cancer Drug Suit
- July 20, 2006 Elan Files Patent Suit Over Breast Cancer Drug
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Archive of over 450,000 articles
- Database of over 2.1 million cases
- 62,000+ organization-specific pages.
- Daily and real-time news and case alerts on organizations, industries, and customized search queries.
- Significant legal events involving law firms, companies, industries, and government agencies.
- Learn more
TRY LAW360 FREE FOR SEVEN DAYS
View all the results
Already a subscriber? Click here to login